Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

177Lu girentuximab

Radiopharmaceutical · developed by Telix Pharmaceuticals Pty

Phase 1/2 Most advanced trial
TLX Developer
1 Registered trials

What is 177Lu girentuximab?

177Lu girentuximab is a radiopharmaceutical comprising the monoclonal antibody girentuximab conjugated to lutetium-177, a beta-emitting radionuclide. It targets carbonic anhydrase IX (CA9), a tumor-associated antigen highly expressed in clear cell renal cell carcinoma. The drug delivers targeted radiation to CA9-expressing cancer cells.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Radiopharmaceutical
Therapy area
Oncology
Developer
Telix Pharmaceuticals Pty Limited (TLX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05663710 Phase 1/2 Advanced Cancer Recruiting TLX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced CancerClear Cell Renal Cell Carcinoma

More from Telix Pharmaceuticals Pty

177Lu-TLX591 Phase 3 89Zr-DFOsq-olaratumab Phase 1 Copper Cu 64-DOTA-TLX592 Early Phase 1 Iodine I 131 IPA Phase 1 Lutetium Lu 177 Rosopatamab Tetraxetan Phase 2 Samarium Sm 153-DOTMP Phase 1 Zirconium Zr 89 Girentuximab Phase 3

Follow TLX, the company behind 177Lu girentuximab

See TLX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TLX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.